MYOS RENS TECHNOLOGY INC. MYOS Cash Flow

Myos rens technology inc. (MYOS)

CashFlow / Quarterly

Mar'20	Dec'19	Sep'19	Jun'19	Mar'19	Dec'18	Sep'18	Jun'18	Mar'18	Dec'17	Sep'17	Jun'17	Mar'17	Dec'16	Sep'16	Jun'16	Mar'16	Dec'15	Sep'15	Jun'15	Mar'15	Dec'14	Sep'14	Jun'14	Mar'14	Dec'13	Sep'13	Jun'13	Mar'13	Dec'12	Sep'12	Jun'12	Mar'12	Dec'11	Sep'11	Jun'11	Mar'11
Cash Flows From Operating Activities:
Net loss
-866,000	-1,187,000	-921,000	-1,175,000	-975,000	-65,000	-911,000	-1,034,000	-1,213,000	-1,082,000	-753,000	-1,106,000	-1,117,000	-752,000	-866,000	-1,503,000	-1,220,000	-1,298,000	-1,294,000	-957,000	-1,529,000	-860,000	-2,177,000	-1,000,000	-422,000	-1,409,000	-780,000	-983,806	-1,090,194	-1,018,174	-812,578	-1,584,857	-498,851	-	-	-	-
Adjustments to reconcile net loss to net cash (used in) provided by operating activities:
Depreciation
5,000	32,000	7,000	6,000	7,000	8,000	7,000	9,000	11,000	12,000	13,000	13,000	13,000	13,000	13,000	14,000	14,000	14,000	14,000	13,000	12,000	12,000	13,000	12,000	12,000	-	-	-	-	-	-	-	-	-	-	-	-
Amortization
52,000	87,000	97,000	93,000	72,000	180,000	71,000	72,000	72,000	71,000	72,000	71,000	53,000	53,000	53,000	52,000	52,000	53,000	52,000	53,000	52,000	-	-	-	-	-	0	0	0	20,000	49,451	0	0	-	-	-	-
Net loss
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	1,857,833	-3,474,381	-2,173,525
Depreciation
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	11,000	12,000	8,673	5,327	402	319	240	212	72	99	79	26
Amortization
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	-	-	-	-	-	-	-	-	-	-	-	-
Accretion of contract liability
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-3,000	-3,000	-2,000	-	-3,000	-3,000	-7,000	0	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-
Stock-based compensation
217,000	213,000	22,000	-172,000	243,000	40,000	30,000	42,000	123,000	39,000	39,000	41,000	41,000	128,000	38,000	129,000	97,000	200,000	165,000	278,000	287,000	464,000	502,000	422,000	303,000	292,000	324,000	364,628	354,372	89,631	326,477	306,150	74,516	128,153	910,109	12,333	1,500,000
Provision for inventory reserve
-	-	-	-	-	-	-	-	-	-	-	-	-	13,000	0	58,000	36,000	326,000	371,000	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Impairment charge
-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	0	44,000	0	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Loss on debt conversion
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	123,261	-883,827	0	-	-	-	-
Impairment charges
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	0	0	0	-	-	-	0
Interest expense paid in stock
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	-	43,762	0	0	-	-	-	-
Derivative charges and credits
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-6,000	-3,000	-11,350	-7,650	-16,349	226,140	-204,525	-21,439	1,725,207	-3,481,084	3,775,583	-460,000
Changes in operating assets and liabilities:
(Increase) decrease in accounts receivable
19,000	44,000	28,000	-3,000	-59,000	73,000	3,000	1,000	-3,000	-52,000	166,000	-116,000	57,000	7,000	-6,000	-38,000	-361,000	-306,000	-350,000	-10,000	-300,000	-359,000	-602,000	838,000	850,000	430,000	-18,000	73,164	-42,164	-14,020	213,212	835	-16,005	-	-	-	0
Decrease (increase) in inventories
-96,000	-73,000	-52,000	-9,000	10,000	-65,000	-1,000	-15,000	3,000	-40,000	-34,000	-10,000	3,000	21,000	483,000	37,000	-40,000	-21,000	13,000	362,000	-4,000	44,000	929,000	308,000	718,000	130,000	-2,000	-95,143	-108,857	33,571	-251,834	-81,149	-8,555	-35,857	897,971	-335,830	0
Increase in operating lease right of use asset
14,000	-	-	-	224,000	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
(Increase) in deferred financing cost
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	-	-	-15,451	-34,000	-	-	-	0
(Increase) decrease in prepaid expenses and other current assets
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	52,000	-105,000	-225,000	56,000	622,000	-91,000	-35,000	104,000	-23,000	49,000	24,648	10,352	21,279	-5,708	-128,378	46,540	-144,377	625,676	-540,805	167,342
(Increase) decrease in prepaid expenses and other assets
88,000	-75,000	-49,000	1,132,000	-995,000	-48,000	-4,000	-49,000	-2,000	-337,000	185,000	49,000	181,000	-	-	-	-163,000	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Decrease in operating lease liabilities
-9,000	-	-	-	-231,000	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Increase in accrued interest expense
-13,000	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Decrease in deferred revenue
-	-	-	-	-	-	-	-	-	-10,000	-10,000	20,000	-56,000	0	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Decrease in accounts payable and accrued expenses
-359,000	325,000	-76,000	-72,000	-280,000	220,000	-4,000	-29,000	16,000	-44,000	161,000	-152,000	-121,000	80,000	-144,000	0	-292,000	242,000	48,000	235,000	-54,000	32,000	-557,000	20,000	583,000	232,000	-233,000	109,767	28,233	53,817	-9,452	-224,216	-129,507	322,853	73,199	18,480	14,998
Net cash (used in) provided by operating activities
-944,000	-463,000	-769,000	-1,239,000	104,000	-700,000	-780,000	-781,000	-989,000	-583,000	-677,000	-1,095,000	-1,428,000	-642,000	-858,000	-1,470,000	-703,000	-281,000	-297,000	-697,000	-977,000	-422,000	-1,869,000	-1,602,000	-1,196,000	-1,405,000	-703,000	-492,057	-553,943	-958,011	-677,337	-190,188	-520,171	-233,481	-515,152	-1,041,257	-365,843
Acquisition of intellectual property
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	0	0	0	-	-	-	-
Purchases of fixed assets
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	7,000	12,000	4,000	28,000	10,000	76,771	258,229	4,770	0	820	1,224	-1	1,456	0	1,569
Acquisition of intangible assets
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	748	1,252	36,440	0	0	0	-450,000	0	0	450,000
Decrease in security deposits
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	-	0	0	-10,000	-	-	-	0
Net cash used in investing activities
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	-9,000	-16,000	-4,000	-28,000	-10,000	-77,519	-259,481	-51,210	0	-820	8,776	1	-1,456	0	-451,569
Cash Flows From Financing Activities:
Proceeds from registered direct offering of common stock
228,000	-227,000	10,000	200,000	228,000	-	-	-	296,000	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Deferred offering costs
-	-	-	-	-	-	-	-	-	-	-	-	-	109,000	-109,000	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Deferred offering costs from at-the-market transaction
-	-	-	-	-	-	-	-	-	-23,000	0	0	125,000	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
(Repayments to) advances from related parties
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	227,023	-173,884	-53,139	27,023	60,000	0	0
Note borrowings
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	19,500	-65,000	65,000	0	-	-	-	-
Repayment of notes payable
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	65,000	0	0	350,000	392,500	-24,903	24,903	0
Proceeds from related party promissory note
300,000	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	40,500	-40,500	0	0	-	-	-	0
Proceeds from exercise of warrants, net
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	11,667	0	0	-	-	-	-
Repayments of term note
-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	0	100,000	200,000	100,000	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Deferred offering costs from private placement
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	0	-	-	-	4,735,000	-	-	-	-	0	5,144,990	700,000	1,025,000	85,000	-17,256	985,500	1,427,256
Proceeds from issuance of common stock in private placement
1,030,000	0	0	0	1,850,000	-	-	-	-	1,017,000	1,000	0	1,926,000	-109,000	109,000	0	5,141,000	-	-	-	-	-	-	-	-	-	-	-	0	0	0	0	0	0	0	0	0
Insurance financing note
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	10,487
Offering costs
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	0	-	0	0	-72,000	0	0	0	0	0	-178,800	0	0	-	-	-	0
Net cash provided by financing activities
1,558,000	131,000	7,000	200,000	2,078,000	256,000	731,000	1,059,000	296,000	1,040,000	1,000	0	1,801,000	0	0	0	5,041,000	375,000	-200,000	1,416,000	0	1,351,000	220,000	0	4,663,000	0	0	0	0	-5,000	5,099,380	591,116	621,861	250,051	32,119	971,084	1,416,769
Net increase in cash
614,000	-332,000	-762,000	-1,039,000	2,182,000	-444,000	-49,000	278,000	-693,000	455,000	-676,000	-1,095,000	373,000	-1,023,000	-857,000	-1,471,000	4,338,000	94,000	-512,000	707,000	-977,000	929,000	-1,658,000	-1,618,000	3,463,000	-1,433,000	-713,000	-569,576	-813,424	-1,014,221	4,422,043	400,108	110,466	16,571	-484,489	-70,173	599,357
Interest
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	15,892	0	0	0	0	0	0
Income taxes
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	1,000	2,000	1,000	0	0	2,000	0	-	-	-	2,150	0	1,028	0	1,550	0	0	0	800
Supplemental schedule of non-cash investing and financing activities:
Conversion of related party promissory note payable into shares of common stock
825,000	0	0	0	250,000	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Reclassification of deferred offering costs to additional paid in capital
-	-	0	0	16,000	0	0	0	6,000	23,000	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Accrued capital expenditures
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	3,000	7,000	-	-	0	0	-	-	-	-	-	-	-	-	-	-	-	-
Offering costs paid by stockholder
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	0	0	0	0	0	0	25,000
Conversion of stockholder loan and interest into common stock
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	102,982	443,761	0	-	-	-	-
Conversion of stockholder loan into common stock
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	2,744
Conversion of stockholder loan into capital - no shares issued
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	0	0	0	0	0	0	22,256
Conversion of 9,767 warrants into 1,954 common shares
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	44,050	0	0	-	-	-	-
Note payable - insurance financing
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	0	0	0	0	0	0	42,500
Note issued for accounts payable
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	0	0	0	0	0	0	0
Acquisition of intellectual property through note payable
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	0	0	0	-	-	-	700,000
Financing costs through issuance of restricted common stock
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	0	20,000	0	-	-	-	0